Logo image of SER

SERINA THERAPEUTICS INC. (SER) Stock Fundamental Analysis

NYSEARCA:SER - NYSE Arca - US81751A1088 - Common Stock - Currency: USD

5.42  -0.12 (-2.17%)

Fundamental Rating

2

SER gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 553 industry peers in the Biotechnology industry. The financial health of SER is average, but there are quite some concerns on its profitability. SER has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SER had negative earnings in the past year.
In the past year SER has reported a negative cash flow from operations.
SER had negative earnings in each of the past 5 years.
In the past 5 years SER always reported negative operating cash flow.
SER Yearly Net Income VS EBIT VS OCF VS FCFSER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -165.52%, SER is not doing good in the industry: 86.26% of the companies in the same industry are doing better.
With a Return On Equity value of -654.97%, SER is not doing good in the industry: 80.47% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -165.52%
ROE -654.97%
ROIC N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SER Yearly ROA, ROE, ROICSER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

SER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SER Yearly Profit, Operating, Gross MarginsSER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

6

2. Health

2.1 Basic Checks

SER does not have a ROIC to compare to the WACC, probably because it is not profitable.
SER has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SER has been reduced compared to 5 years ago.
SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SER Yearly Shares OutstandingSER Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SER Yearly Total Debt VS Total AssetsSER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -11.37, we must say that SER is in the distress zone and has some risk of bankruptcy.
SER's Altman-Z score of -11.37 is on the low side compared to the rest of the industry. SER is outperformed by 75.95% of its industry peers.
SER has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.37
ROIC/WACCN/A
WACC9.71%
SER Yearly LT Debt VS Equity VS FCFSER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 2.45 indicates that SER has no problem at all paying its short term obligations.
SER's Current ratio of 2.45 is on the low side compared to the rest of the industry. SER is outperformed by 70.34% of its industry peers.
SER has a Quick Ratio of 2.45. This indicates that SER is financially healthy and has no problem in meeting its short term obligations.
SER has a worse Quick ratio (2.45) than 68.72% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
SER Yearly Current Assets VS Current LiabilitesSER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.97% over the past year.
SER shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -60.56%.
SER shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -49.65% yearly.
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.73%
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 4.65% on average over the next years.
SER is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -25.99% yearly.
EPS Next Y-30.09%
EPS Next 2Y-1.03%
EPS Next 3Y4.65%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SER Yearly Revenue VS EstimatesSER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SER Yearly EPS VS EstimatesSER Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SER. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SER Price Earnings VS Forward Price EarningsSER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SER Per share dataSER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.03%
EPS Next 3Y4.65%

More info and screens

0

5. Dividend

5.1 Amount

SER does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERINA THERAPEUTICS INC.

NYSEARCA:SER (8/1/2025, 3:57:19 PM)

5.42

-0.12 (-2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-08 2025-08-08
Inst Owners3.4%
Inst Owner Change0%
Ins Owners18.75%
Ins Owner Change40.94%
Market Cap54.04M
Analysts80
Price Target13.26 (144.65%)
Short Float %1.08%
Short Ratio1.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)18.18%
PT rev (3m)18.18%
EPS NQ rev (1m)13.27%
EPS NQ rev (3m)15%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 964.95
P/FCF N/A
P/OCF N/A
P/B 31.77
P/tB 31.77
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS0.01
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -165.52%
ROE -654.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-204.08%
ROA(5y)-232.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.3%
Cap/Sales 14.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z -11.37
F-Score3
WACC9.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.73%
EPS Next Y-30.09%
EPS Next 2Y-1.03%
EPS Next 3Y4.65%
EPS Next 5YN/A
Revenue 1Y (TTM)-60.56%
Revenue growth 3Y-26.32%
Revenue growth 5Y-49.65%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-71.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-222.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-222.24%
OCF growth 3YN/A
OCF growth 5YN/A